Genscript Biotech First Half 2025 Earnings: US$0.012 loss per share (vs US$0.046 loss in 1H 2024)

Genscript Biotech (HKG:1548) First Half 2025 Results

Key Financial Results

• Revenue: US$518.8m (up 82% from 1H 2024).
• Net loss: US$25.5m (loss narrowed by 74% from 1H 2024).
• US$0.012 loss per share (improved from US$0.046 loss in 1H 2024).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Genscript Biotech Earnings Insights

Looking ahead, revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in Hong Kong.

Performance of the Hong Kong Life Sciences industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

We should say that we've discovered 2 warning signs for Genscript Biotech that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.